Australian Clinical Labs (ASX:ACL) Ending Cash Position: A$22.4 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ACL Australian Clinical Labs Ltd ASX:ACL
56 GF Score
Price A$2.38
GF Value A$3.06
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Australian Clinical Labs Ending Cash Position?

Australian Clinical Labs ASX:ACL -0.83% 56 Ending Cash Position is A$22.4 Mil as of Dec. 2025. GuruFocus rates ASX:ACL with a GF Score™ of 56/100 and a GF Value™ of A$3.06 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Australian Clinical Labs's Ending Cash Position for the quarter that ended in Dec. 2025 was A$22.4 Mil.

Australian Clinical Labs's quarterly Ending Cash Position increased from Dec. 2024 (A$20.8 Mil) to Jun. 2025 (A$21.4 Mil) and increased from Jun. 2025 (A$21.4 Mil) to Dec. 2025 (A$22.4 Mil).

Australian Clinical Labs's annual Ending Cash Position increased from Jun. 2023 (A$20.0 Mil) to Jun. 2024 (A$26.1 Mil) but then declined from Jun. 2024 (A$26.1 Mil) to Jun. 2025 (A$21.4 Mil).

Australian Clinical Labs Ending Cash Position Related Terms

Australian Clinical Labs Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Australian Clinical Labs's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Australian Clinical Labs Ending Cash Position Chart

Australian Clinical Labs Annual Data
Trend Dec20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial 35.23 26.37 19.96 26.14 21.44

Australian Clinical Labs Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 24.94 26.14 20.81 21.44 22.43
ASX:ACL
56GF Score
Australian Clinical Labs Ltd ASX:ACL
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Australian Clinical Labs Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Australian Clinical Labs's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=26.136+-4.694
=21.4

Australian Clinical Labs's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.033999999999995+22.398
=22.4

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$22.4 Mil mean?
Australian Clinical Labs (ASX:ACL) has a Ending Cash Position of A$22.4 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Australian Clinical Labs and its competitors.
Is Australian Clinical Labs' Ending Cash Position too high?
Australian Clinical Labs' current Ending Cash Position is A$22.4 Mil. Overall, Australian Clinical Labs has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' Ending Cash Position compare to TMO and DHR?
Australian Clinical Labs' Ending Cash Position of A$22.4 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Australian Clinical Labs and its competitors. Australian Clinical Labs's current Ending Cash Position is A$22.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Modestly Undervalued. The stock's GF Value™ is A$3.06, compared to a current price of A$2.38 — trading 22.2% below its estimated fair value. The current Ending Cash Position is A$22.4 Mil. Australian Clinical Labs' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current Ending Cash Position is A$22.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?

Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued. The current stock price of A$2.38 is trading 22.2% below its estimated GF Value™ of A$3.06. GuruFocus considers Australian Clinical Labs to be Modestly Undervalued.

Key valuation signals for ASX:ACL:

  • Ending Cash Position: A$22.4 Mil
  • GF Value™: A$3.06 vs. price of A$2.38 (22.2% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Australian Clinical Labs Business Description

Address 1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
56GF Score

Get the complete analysis for ASX:ACL

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.38
Price
A$3.06
GF Value